Healthy
Conditions
Keywords
Bioequivalence, Healthy Subjects
Brief summary
The objective of this study is to compare the relative bioavailability of glimepiride 4 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of AMARYL® tablets (Aventis) in healthy, adult, non-smoking subjects under non-fasting conditions.
Detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods
Interventions
1 x 4 mg, single-dose non-fasting
1 x 4 mg, single-dose non-fasting
Sponsors
Teva Pharmaceuticals USA
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All subjects selected for this study will be non-smokers at least 18 years of age. Subjects will have a BMI (body mass index) of 30 or less. * Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history. * Each female subject will be given a serum pregnancy test as part of the pre-study screening process. Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements. Clinical laboratory measurements will include the following: * Hematology: hemoglobin, hematocrit, red blood cell count, platelets, whit blood cell count (with differential). * Clinical Chemistry: creatinine, BUN, glucose, SGOT/AST, SGPT/ALT, bilirubin, and alkaline phosphatase. * Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells. * HIV Screen: pre-study only. * Hepatitis-B, C Screen: pre-study only. * Drugs of Abuse Screen: pre-study and at each check-in. Subjects will be selected if all above are normal.
Exclusion criteria
* Subjects with a significant recent history of chronic alcohol consumption, drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study. * Subjects whose clinical laboratory test values are greater than 20% outside the normal range may be retested. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant. * Subjects who have a history of allergic responses to the class of drug being tested will be excluded from the study. * Subjects who use tobacco in any form will not be eligible to participate in the study. Three months abstinence is required. * All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each dosing period check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate. * Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study. * Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate. * Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of childbearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate. Female subjects who have used hormonal oral contraceptives within 14 days of dosing or implanted or injected hormonal contraceptives within 180 days of dosing will not be allowed to participate. * All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study. * Subjects who do not tolerate venipuncture will not be allowed to participate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax - Maximum Observed Concentration | Blood samples collected over 24 hour period | Bioequivalence based on Cmax |
| AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) | Blood samples collected over 24 hour period | Bioequivalence based on AUCinf |
| AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) | Blood samples collected over 24 hour period | Bioequivalence based on AUC0-t |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Glimepiride (Test) First Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period | 16 |
| Amaryl® (Reference) First Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period | 16 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Washout | Protocol Violation | 0 | 1 |
Baseline characteristics
| Characteristic | Glimepiride (Test) First | Amaryl® (Reference) First | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 16 Participants | 16 Participants | 32 Participants |
| Race/Ethnicity, Customized Biracial | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Black | 8 Participants | 9 Participants | 17 Participants |
| Race/Ethnicity, Customized Caucasian | 6 Participants | 3 Participants | 9 Participants |
| Race/Ethnicity, Customized Hispanic | 2 Participants | 3 Participants | 5 Participants |
| Region of Enrollment United States | 16 participants | 16 participants | 32 participants |
| Sex: Female, Male Female | 6 Participants | 10 Participants | 16 Participants |
| Sex: Female, Male Male | 10 Participants | 6 Participants | 16 Participants |
Outcome results
Primary
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
Bioequivalence based on AUC0-t
Time frame: Blood samples collected over 24 hour period
Population: Data from all subjects who completed the study were included in the statistical analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Glimepiride | AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) | 1639.083 ng*h/mL | Standard Deviation 846.547 |
| Amaryl® | AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) | 1632.301 ng*h/mL | Standard Deviation 969.908 |
90% CI: [99.3, 106]
Primary
AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Bioequivalence based on AUCinf
Time frame: Blood samples collected over 24 hour period
Population: The parameter of AUCinf could not be estimated for three subjects.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Glimepiride | AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) | 1751.420 ng*h/mL | Standard Deviation 1071.151 |
| Amaryl® | AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) | 1824.742 ng*h/mL | Standard Deviation 1346.454 |
90% CI: [96.8, 105]
Primary
Cmax - Maximum Observed Concentration
Bioequivalence based on Cmax
Time frame: Blood samples collected over 24 hour period
Population: Data from all subjects who completed the study were included in the statistical analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Glimepiride | Cmax - Maximum Observed Concentration | 267.629 ng/mL | Standard Deviation 101.151 |
| Amaryl® | Cmax - Maximum Observed Concentration | 266.706 ng/mL | Standard Deviation 107.927 |
90% CI: [92.1, 112]